SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549-1004
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (date of earliest event reported): May 6, 2004
Ciphergen Biosystems, Inc.
(Exact name of Registrant as specified in its charter)
Delaware 000-31617 33-059-5156
(State or other jurisdiction of [Commission File Number] (I.R.S. Employer
incorporation or organization) Identification Number)
6611 Dumbarton Circle
Fremont, CA 94555
(Address of principal executive offices)
(510) 505-2100
(Registrant's telephone number, including area code)
Item 7. Financial Statements and Exhibits
(c) Exhibits.
99.1 Press Release, dated May 6, 2004.
Item 12. Results of Operations and Financial Condition
On May 6, 2004, Ciphergen Biosystems, Inc. issued a press release
announcing financial results for its fiscal first quarter ended March 31, 2004.
The press release is attached as Exhibit 99.1 to this Form 8-K.
The information in this Current Report is being furnished and shall not be
deemed "filed" for purposes of Section 18 of the Securities and Exchange Act of
1934, as amended, or otherwise subject to the liabilities of that Section. The
information in this Current Report shall not be incorporated by reference into
any registration statement or other document pursuant to the Securities Act of
1933, as amended.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Ciphergen Biosystems, Inc.
(Registrant)
Date: May 6, 2004 By: /s/ William Rich
-----------------------------------------
William E. Rich
President and Chief Executive Officer
EXHIBIT INDEX
Exhibit
Number Description
------- -----------------------------------------------------------------
99.1 Press Release issued by Ciphergen Biosystems, Inc. on May 6, 2004